[EN] 8-(AZETIDIN-1-YL)-[1,2,4]TRIAZOLO[1,5-A]PYRIDINYL COMPOUNDS, COMPOSITIONS AND METHODS OF USE THEREOF<br/>[FR] COMPOSÉS DE 8-(AZÉTIDIN-1-YL)-[1,2,4]TRIAZOLO[1,5-A]PYRIDINYLE, COMPOSITIONS ET PROCÉDÉS D'UTILISATION DE CEUX-CI
申请人:HOFFMANN LA ROCHE
公开号:WO2018046409A1
公开(公告)日:2018-03-15
Compounds of Formuula (I) and (II), or a stereoisomer, tautomer, solvate, prodrug or salt thereof, and methods of use as Janus kinase inhibitors are described herein.
JANUS KINASES INHIBITORS, COMPOSITIONS THEREOF AND USE THEREOF
申请人:F. Hoffmann-La Roche AG
公开号:EP3380474A1
公开(公告)日:2018-10-03
8-(AZETIDIN-1-YL)-[1,2,4]TRIAZOLO[1,5-A]PYRIDINYL COMPOUNDS, COMPOSITIONS AND METHODS OF USE THEREOF
申请人:F. Hoffmann-La Roche AG
公开号:EP3510030A1
公开(公告)日:2019-07-17
THERAPEUTIC COMPOUNDS AND COMPOSITIONS, AND METHODS OF USE THEREOF
申请人:Genentech, Inc.
公开号:US20180265515A1
公开(公告)日:2018-09-20
Compounds of Formula (00A) and salts thereof, wherein R
1
, R
2
R
3
, R
4
and n are defined herein, are useful as inhibitors of one or more Janus kinases. Also provided are pharmaceutical compositions that include a compound of Formula (00A) and a pharmaceutically acceptable carrier, adjuvant or vehicle, and methods of treating or lessening the severity of a disease or condition responsive to the inhibition of a Janus kinase activity in a patient.
INHALED POWDER FORMULATIONS
申请人:Genentech, Inc.
公开号:US20200165260A1
公开(公告)日:2020-05-28
Compounds of Formula (00A) and salts thereof, wherein R
1
, R
2
R
3
, R
4
and n are defined herein, are useful as inhibitors of one or more Janus kinases. Also provided are pharmaceutical compositions that include a compound of Formula (00A) and a pharmaceutically acceptable carrier, adjuvant or vehicle, and methods of treating or lessening the severity of a disease or condition responsive to the inhibition of a Janus kinase activity in a patient.